5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | NEUTRAL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.63▼ | 6.60▼ | 6.59▼ | 6.72▼ | 5.93▲ |
MA10 | 6.68▼ | 6.70▼ | 6.72▼ | 7.39▼ | 3.42▲ |
MA20 | 6.79▼ | 6.85▼ | 6.88▼ | 6.13▲ | 2.25▲ |
MA50 | 7.01▼ | 7.44▼ | 7.61▼ | 3.02▲ | 1.45▲ |
MA100 | 7.69▼ | 7.62▼ | 5.89▲ | 2.01▲ | 1.25▲ |
MA200 | 7.69▼ | 4.21▲ | 3.28▲ | 1.44▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.012▼ | -0.004▼ | -0.010▼ | -0.270▼ | 0.712▲ |
RSI | 31.855▼ | 33.504▼ | 33.294▼ | 59.737▲ | 68.986▲ |
STOCH | 28.509 | 22.149 | 9.420▼ | 12.206▼ | 56.521 |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -100.000▼ | -33.370 |
CCI | -180.507▼ | -170.322▼ | -161.691▼ | -98.733 | 109.742▲ |
Thursday, August 07, 2025 09:27 AM
IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Patient Dosed in Phase 3 OVATION 3 Trial On July 30, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first patient has been dosed in ...
|
Wednesday, August 06, 2025 12:45 AM
Imunon Inc (IMNN) reports significant progress in ovarian cancer treatment trials while navigating a tough capital market environment.
|
Tuesday, August 05, 2025 01:19 PM
Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 6.45 | 6.75 | 6.40 | 6.40 | 36,361 |
14/08/25 | 6.71 | 6.988 | 6.4233 | 6.60 | 64,155 |
13/08/25 | 6.84 | 7.2138 | 6.70 | 6.70 | 95,639 |
12/08/25 | 6.89 | 7.19 | 6.65 | 6.84 | 74,893 |
11/08/25 | 7.12 | 7.21 | 6.85 | 7.08 | 34,595 |
08/08/25 | 7.28 | 7.28 | 6.8588 | 7.18 | 57,018 |
07/08/25 | 7.33 | 7.5499 | 6.45 | 6.95 | 213,187 |
06/08/25 | 8.83 | 8.9123 | 8.09 | 8.215 | 87,555 |
05/08/25 | 8.805 | 9.12 | 8.2301 | 8.76 | 133,804 |
04/08/25 | 8.50 | 9.42 | 8.50 | 9.20 | 98,436 |
|
|
||||
|
|
||||
|
|